FDA wants a shift away from animal testing
FDA wants to get rid of animal testing requirements for antibody drugs
Insight on FDA’s Plan to Phase Out Animal Testing for mAbs and Other Drugs
Infinimmune Appoints Dr. Tim Sullivan as Chief Business Officer
Dr. Sullivan, who has decades of experience as a senior executive in the biotechnology and pharmaceutical industry, will be responsible for corporate and business development initiatives, as well as corporate and product strategic planning.
Infinimmune Appoints Dr. Neela Patel to Board of Directors
Dr. Patel is a seasoned life sciences executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong drug development expertise, including a track record of successful U.S. and global pharmaceutical licensing deals.
Biotech Showcase: Removing Barriers – Healthcare Access and Equity for All
Join Wyatt McDonnell as he appears as a panelist during this event.
Infinimmune, Grid Therapeutics Strike Antibody-Based Cancer Drug Discovery Partnership
RESI JPM 2024 Big Pharma Panel
Join us as Wyatt McDonnell moderates this RESI panel.
Infinimmune Announces Partnership with Grid Therapeutics to Conduct Deep Sequencing of B Cells for Oncology Drug Discovery
“Infinimmune, a biotechnology company pioneering new methods for antibody drug discovery and development, today announced a partnership with Grid Therapeutics (“Grid”), a clinical stage biotechnology company that focuses on human-derived antibodies, to collaborate in identifying new antibody drug candidates for non-small cell lung cancer.”
Bio’s Next Tool Builders
Infinimmune’s founding team are tool builders who design from first principles and have broad expertise across immunology, single cell technologies, protein engineering, computational biology, and genome assembly.Transforming human antibodies into drugs.